Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Cash from Operations of 30122000.0 for Q4 2025, up 31.1% year-over-year from 22975921.0 in Q4 2024, and up 10.94% quarter-over-quarter from 33824000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Cash from Operations for 3 consecutive years, with 30122000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 31.1% year-over-year to 30122000.0; the TTM figure through Dec 2025 stood at 129794000.0 (up 33.24% YoY), while the FY2025 annual figure was 129794000.0, up 33.24% from the prior year.
- Cash from Operations rose to 30122000.0 in Q4 2025 per INBX's latest filing, from 33824000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 29953000.0 in Q2 2025 and bottomed at 63050000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 43526900.0 across 3 years, with a median of 39807500.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 47.78% in 2025 and fell as far as 11.7% in 2025.
- Inhibrx Biosciences' Cash from Operations stood at 56821000.0 in 2023, then rose by 23.06% to 43720000.0 in 2024, then soared by 31.1% to 30122000.0 in 2025.
- Business Quant data shows INBX's Cash from Operations at 30122000.0 in Q4 2025, 33824000.0 in Q3 2025, and 29953000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -30.12 Mn |
| Sep 30, 2025 | -33.82 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Dec 31, 2024 | -43.72 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Jun 30, 2024 | -57.36 Mn |
| Mar 31, 2024 | -63.05 Mn |
| Dec 31, 2023 | -56.82 Mn |
| Sep 30, 2023 | -54.25 Mn |